Does applying technology throughout the medication use process improve patient safety with antineoplastics?

Area of Science:

• Oncology
• Health Informatics
• Patient Safety

Background:

• Medication errors are a significant concern in patient care, particularly with complex antineoplastic agents.
• Systemic issues often contribute to medication errors, highlighting the need for technological solutions.
• Antineoplastic therapies require precise administration due to narrow therapeutic indices and complex regimens.

Purpose of the Study:

• To review the advantages and disadvantages of current technologies in managing antineoplastic therapy.
• To assess the impact of technology on medication errors, documentation, costs, and efficiency in cancer care.
• To evaluate the evidence supporting the use of various technologies in the antineoplastic medication use process.

Main Methods:

• Review of existing literature on healthcare technologies and their application to medication use.
• Analysis of the effectiveness of specific technologies like CPOE, BCMA, smart pumps, eMAR, and telepharmacy.
• Evaluation of the evidence base for technology adoption in antineoplastic therapy.

Main Results:

• Several technologies (CPOE, BCMA, smart pumps, eMAR, telepharmacy) are proven to reduce errors and improve outcomes in general patient populations.
• The adoption and documented effectiveness of these technologies in antineoplastic therapy are currently limited.
• Computerized provider order entry (CPOE) is the only technology with substantial evidence supporting reduced medication errors in cancer patients.

Conclusions:

• Technology can mitigate, but not entirely prevent, medication errors.
• The evidence supporting technology's role in preventing medication errors is limited, especially for antineoplastic treatments.
• While CPOE shows promise, the benefits of other technologies in cancer care may need to be inferred from broader patient data; critical assessment of new technologies is essential.